Genenta Science S.p.A. (NASDAQ:GNTA – Get Free Report) was the target of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 5,000 shares, an increase of 47.1% from the May 31st total of 3,400 shares. Based on an average daily volume of 4,300 shares, the short-interest ratio is presently 1.2 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Genenta Science in a research report on Monday, May 13th.
Check Out Our Latest Analysis on Genenta Science
Genenta Science Stock Performance
About Genenta Science
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Read More
- Five stocks we like better than Genenta Science
- What is a Dividend King?
- Applied Digital Boosts Stock with Cutting-Edge AI Data Centers
- With Risk Tolerance, One Size Does Not Fit All
- Chewy Stock Surges on Roaring Kitty’s Disclosure of Major Stake
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- How to Invest in Gold: A Complete Guide
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.